Apcor R&M SRL
Apcor R&M reported total assets of 5,677 € at the end of the 2025 financial year (annual accounts filed with the NBB on 31 Aug 2026).
The score of Apcor R&M shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets -85 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Apcor R&M's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Aug 2026
- Year ended 31 Dec 2024filed on 29 Aug 2025
- Year ended 31 Dec 2023filed on 29 Aug 2024
- Year ended 31 Dec 2022filed on 31 Aug 2023
- Year ended 31 Dec 2021filed on 27 Aug 2022
Apcor R&M's financial analysis
- Solvency-6326.8%sector median: 56.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Apcor R&M
Apcor R&M's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0600.952.909
- VAT number
- BE0600952909
- Peppol
- Registered · 0208:0600952909 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 10 Mar 2015
- Registered office
- 9052 Ghent
- Latest accounts
- 2025 · filed on 31 Aug 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
Apcor R&M (SRL) has been based in Ghent since 2015, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net loss of 14,763 € and equity of −359,177 €; its revenue is not published. Its solvency stands at -6326.8%, below the median of its sector (56.0%).
Companies similar to Apcor R&M
Companies in the same business, of comparable size and area, outside its group.
- Raya Therapeutic Manufacture of basic pharmaceutical products Leuven · balance sheet 5,330 €
- MC Pharma Manufacture of basic pharmaceutical products Beaumont · balance sheet 28,699 €
- Invigo Therapeutics Manufacture of pharmaceutical preparations Mechelen · balance sheet 2,055 €
- Estrella Clinical Research Manufacture of basic pharmaceutical products Herentals · balance sheet 41,482 €
- Inchinn Therapeutics Manufacture of basic pharmaceutical products Charleroi · balance sheet 51,394 €
- Pranarom MED Manufacture of basic pharmaceutical products Ath · balance sheet 24,820 €
- Biomdrin Manufacture of pharmaceutical preparations Schilde · balance sheet 38,268 €
- RheADC Manufacture of basic pharmaceutical products Leuven · balance sheet 31,395 €
Frequently asked questions about Apcor R&M
What is the revenue of Apcor R&M?
Apcor R&M files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Apcor R&M?
In Belgium, the VAT number is the company number prefixed with BE: BE0600952909 for Apcor R&M, if the company is VAT-registered. Its company number (CBE) is 0600.952.909.
Where is the registered office of Apcor R&M?
According to the CBE register, the registered office of Apcor R&M is in 9052 Ghent.
What is the equity of Apcor R&M?
At the close of the 2025 financial year, the equity of Apcor R&M amounts to -359,177 €, a solvency of -6326.8% of total assets.
Who manages Apcor R&M?
The register lists 2 active mandates at Apcor R&M. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Apcor R&M
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →